Search Results Search Sort by RelevanceMost Recent Case and Commentary Mar 2006 The Pitfalls of Drug Company Sample Use Robert Goodman, MD Virtual Mentor. 2006;8(3):138-141. doi: 10.1001/virtualmentor.2006.8.3.ccas3-0603. Case and Commentary Feb 2013 Quality Improvement of Economic Profiling Marguerite Huff Virtual Mentor. 2013;125-130. doi: 10.1001/virtualmentor.2013.15.2.bndr2-1302. Case and Commentary Jul 2003 Drug Company Sponsorship of Clinical Conferences, Commentary 1 Robert Goodman, MD Virtual Mentor. 2003;5(7):239-241. doi: 10.1001/virtualmentor.2003.5.7.ccas1-0307. Case and Commentary Jul 2003 Drug Company Sponsorship of Clinical Conferences, Commentary 2 Ashley Wazana, MD Virtual Mentor. 2003;5(7):242-246. doi: 10.1001/virtualmentor.2003.5.7.ccas1-0307. Case and Commentary Jul 2003 Clinician and Researcher, Commentary 1 Timothy F. Murphy, PhD Virtual Mentor. 2003;5(7):247-250. doi: 10.1001/virtualmentor.2003.5.7.ccas2-0307. Case and Commentary Jul 2003 Clinician and Researcher, Commentary 2 Matthew Wynia, MD Virtual Mentor. 2003;5(7):251-254. doi: 10.1001/virtualmentor.2003.5.7.ccas2-0307. Case and Commentary Apr 2014 Drug Samples: Why Not? Ly Le Tran, MD, JD In the view of the author, the benefits of drug sampling outweigh the risks. Virtual Mentor. 2014;16(4):245-251. doi: 10.1001/virtualmentor.2014.16.4.ecas2-1404.
Case and Commentary Mar 2006 The Pitfalls of Drug Company Sample Use Robert Goodman, MD Virtual Mentor. 2006;8(3):138-141. doi: 10.1001/virtualmentor.2006.8.3.ccas3-0603.
Case and Commentary Feb 2013 Quality Improvement of Economic Profiling Marguerite Huff Virtual Mentor. 2013;125-130. doi: 10.1001/virtualmentor.2013.15.2.bndr2-1302.
Case and Commentary Jul 2003 Drug Company Sponsorship of Clinical Conferences, Commentary 1 Robert Goodman, MD Virtual Mentor. 2003;5(7):239-241. doi: 10.1001/virtualmentor.2003.5.7.ccas1-0307.
Case and Commentary Jul 2003 Drug Company Sponsorship of Clinical Conferences, Commentary 2 Ashley Wazana, MD Virtual Mentor. 2003;5(7):242-246. doi: 10.1001/virtualmentor.2003.5.7.ccas1-0307.
Case and Commentary Jul 2003 Clinician and Researcher, Commentary 1 Timothy F. Murphy, PhD Virtual Mentor. 2003;5(7):247-250. doi: 10.1001/virtualmentor.2003.5.7.ccas2-0307.
Case and Commentary Jul 2003 Clinician and Researcher, Commentary 2 Matthew Wynia, MD Virtual Mentor. 2003;5(7):251-254. doi: 10.1001/virtualmentor.2003.5.7.ccas2-0307.
Case and Commentary Apr 2014 Drug Samples: Why Not? Ly Le Tran, MD, JD In the view of the author, the benefits of drug sampling outweigh the risks. Virtual Mentor. 2014;16(4):245-251. doi: 10.1001/virtualmentor.2014.16.4.ecas2-1404.